3:45 PM Abstract No. 376 Clear cell hepatocellular carcinoma is associated with non-viral cirrhosis and arterial-phase hypo-enhancement but does not predict outcome after locoregional therapy

医学 肝细胞癌 肝硬化 胃肠病学 比例危险模型 危险系数 经皮 活检 内科学 放射科 肿瘤科 置信区间
作者
B. Park,Ruchi Gaba,Yi Huang,Y. Chen,Gabriela Guzmán,R. Peter Lokken
出处
期刊:Journal of Vascular and Interventional Radiology [Elsevier]
卷期号:29 (4): S161-S161
标识
DOI:10.1016/j.jvir.2018.01.417
摘要

Clear cell hepatocellular carcinoma (HCC) is a less common HCC cytologic variant associated with improved outcomes in studies prior to the advent of locoregional therapy (LRT). This study was undertaken to determine whether clear cell HCC predicts better outcomes after LRT. We retrospectively identified 124 consecutive patients (92 men, 32 women; median age 59 y) with 132 HCC (mean diameter 4.8 ± 3.9 cm) diagnosed by percutaneous biopsy between 2008-2017 prior to transarterial chemoembolization (TACE) (n = 51, 41%), yttrium-90 radioembolization (n = 17, 13%), percutaneous thermal ablation (n = 41, 33%), and combination TACE/ablation (n = 15, 12%). Baseline Barcelona Clinic Liver Cancer (BCLC) stage was 0/A (n = 48, 38%), B (n = 33, 26%), C (n = 27, 22%), and D (n = 16, 13%). Cytological subtype was determined from percutaneous core needle biopsy as 100% clear cells, focal clear cells, or no clear cells. Baseline clinical and imaging features, and radiologic response by mRECIST were correlated with cytological subtype using multinomial regression analysis. Time to progression (TTP) and transplant free survival (TFS) were analyzed by Cox proportional hazard models. Percutaneous core biopsies comprised entirely of clear cell subtype were associated with non-viral etiologies of HCC (OR 5.3 95% CI 1.64-17.16; p = 0.005), solid histological arrangement (OR 4.32 95% CI 1.14-16.37; p = 0.031), and hypo-enhancement on arterial phase CT or MRI images (OR 3.08 95% CI 1.02-9.3; p = 0.046). The clear cell subtype was not associated with improved objective response by mRECIST (OR 0.93 95% CI 0.37-2.33; p = 0.87), delayed TTP (HR 1.17 95% CI 0.86-1.6; p = 0.32), or better TFS (HR 1.01 95% CI 0.69-1.47; p = 0.96) in comparison to specimens with focal or no clear cells. There remained no significant association between the clear cell subtype and TTP or TFS after stratifying by LRT modalities. Clear cell HCC is more common in non-viral etiologies of cirrhosis and is associated with atypical enhancement on radiologic images. It does not, however, impart independent prognostic information prior to LRT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Suagy完成签到 ,获得积分10
2秒前
dichloro完成签到,获得积分20
2秒前
2秒前
斯文败类应助Star采纳,获得30
3秒前
4秒前
5秒前
6秒前
Orange应助levicho采纳,获得10
6秒前
纯真硬币发布了新的文献求助10
6秒前
万能图书馆应助帅发采纳,获得10
6秒前
yeerenn发布了新的文献求助10
9秒前
weilong完成签到,获得积分10
9秒前
东东完成签到 ,获得积分10
11秒前
简单完成签到 ,获得积分10
11秒前
dichloro发布了新的文献求助10
11秒前
12秒前
传奇3应助dy1994采纳,获得10
12秒前
13秒前
14秒前
愤怒也呵呵完成签到,获得积分10
15秒前
BruceQ发布了新的文献求助10
17秒前
柠檬发布了新的文献求助10
17秒前
17秒前
冰阔罗发布了新的文献求助10
18秒前
帅发发布了新的文献求助10
18秒前
睡不醒也吃不饱完成签到 ,获得积分10
19秒前
19秒前
23秒前
宁静致远QY完成签到,获得积分10
24秒前
25秒前
25秒前
桐桐应助cycycycy采纳,获得10
25秒前
levicho发布了新的文献求助10
26秒前
27秒前
27秒前
28秒前
心向发布了新的文献求助10
28秒前
搜集达人应助冰阔罗采纳,获得10
28秒前
PKQ完成签到,获得积分10
28秒前
30秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3140687
求助须知:如何正确求助?哪些是违规求助? 2791513
关于积分的说明 7799229
捐赠科研通 2447844
什么是DOI,文献DOI怎么找? 1302096
科研通“疑难数据库(出版商)”最低求助积分说明 626439
版权声明 601194